• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Nexstim

9.49 EUR+1.28 %31.7. klo 18.29
5,669 following

NXTMH

First North Finland

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+1.28 %
-1.04 %
+16.58 %
-27.00 %
-33.17 %
-37.36 %
+173.49 %
+137.25 %
-98.43 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
76.63M EUR
Turnover
139.94K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Accumulate
Target price
Updated
14.05.2026
Disclaimer
Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Press releases
ShowingAll content types

Forum discussions
On what grounds do you arrive at such a bleak earnings forecast despite the good growth?
yesterday
by Puutaheinää
10
Finnish Private Clinic Group Orders Additional Nexstim NBS 6 System NXTMHLehdistötiedote07/31/2026, 01:00 PM Nexstim Plc (“Nexstim” or “Company”) has received an order for one NBS 6 therapy system from a customer in Finland. The customer is a private healthcare provider and existing...
yesterday
by Index
10
I started thinking about those two 10-unit NBS6 orders. The first was announced on June 11, with the machines to be delivered in H1 and H2. The second one came on July 14, and those machines are to be delivered in H2. Sales pipelines have previously been 1–1.5 years. The question...
yesterday
by Jatast
9
The average number of orders for H2 2024/2025 is approximately 20 (excluding Sinaptica), and now in July it’s 16, so the growth base looks really good. I won’t even bother guessing the figures, as I would have been way off for July already. Real growth is definitely on the horizon...
yesterday
by Taitoo
8
Good point that they might have ordered them for stock. But on the other hand, since that second order came just a month after the previous one, one would imagine that at least the first set of ten would have been sold already. Otherwise, there would have been time to wait until ...
yesterday
by Informaatio
6
My current view is that for intracranial BCI, Nexstim’s business case is currently small. In my opinion, the problem is that these implants are installed in the operating room, which makes it slow and expensive—it doesn’t scale. Nexstim is needed to find the correct installation ...
5 hours ago
by AccionHombre
3
A new perspective for me is that Brainlab might have bought for their inventory. It’s entirely possible. The number of deals announced in H1 has also increased for two years now. Could it be that hospitals are finally starting to see this product as genuinely useful and necessary...
yesterday
by Tee
3
Read more on our forum
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 15.05.2026

Latest extensive report

Released: 26.06.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
14.8.
2026

Interim report Q2'26

Press release31.07.2026 klo 13.00

Finnish Private Clinic Group Orders Additional Nexstim NBS 6 System

Nexstim
Regulatory press release20.07.2026 klo 13.00

Nexstim Plc: Disclosure of major holdings under Chapter 9, Section 10 of the Finnish Securities Markets Act

Nexstim
Press release17.07.2026 klo 09.00

Delve Psychiatry Upgrades to Nexstim's Latest NBS 6 Platform

Nexstim

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release15.07.2026 klo 09.00

Nexstim Receives NBS 6 Therapy System Order from a Neurology Clinic in the United States

Nexstim
Nexstim received another order for ten NBS 6 systems
Analyst Comment15.07.2026 klo 09.01 by
Frans-Mikael Rostedt

Nexstim received another order for ten NBS 6 systems

The second order for ten systems within a month indicates the rapid scaling of the distribution partnership.

Nexstim
Press release14.07.2026 klo 09.00

Nexstim Receives a New Order for Ten NBS 6 Systems from Distributor

Nexstim
Press release10.07.2026 klo 09.00

Nexstim Receives Expanded Health Canada Approval for NBS 6 Diagnostics and Pain Applications

Nexstim
Press release08.07.2026 klo 09.00

Nexstim Secures First NBS 6 Sale Following Malaysian Market Authorization

Nexstim
Press release07.07.2026 klo 09.00

Nexstim Receives Malaysian Authorization for Commercial Distribution of NBS System 6

Nexstim
New NBS 6 system order for Nexstim from USA
Analyst Comment06.07.2026 klo 09.17 by
Atte Riikola

New NBS 6 system order for Nexstim from USA

This is a new customer for the company

Nexstim
Press release03.07.2026 klo 09.00

Nexstim Receives NBS 6 Therapy System Order from New Customer in the United States

Nexstim
Significant one-time order for Nexstim
Analyst Comment12.06.2026 klo 09.28 by
Antti Siltanen

Significant one-time order for Nexstim

The one-time order for ten systems strengthens our confidence in this year's growth estimates.

Nexstim
Press release11.06.2026 klo 09.00

Nexstim Receives Order for Ten NBS 6 Systems from Distributor

Nexstim
Nexstim received a new sales authorization for the NBS 6 system in Australia
Analyst Comment04.06.2026 klo 08.48 by
Antti Siltanen

Nexstim received a new sales authorization for the NBS 6 system in Australia

The sales authorization expands the use of the NBS 6 system to diagnostics and rehabilitation.

Nexstim
Press release03.06.2026 klo 10.00

Nexstim granted authorization for commercial distribution of NBS System 6 for use in diagnostics and post-operative rehabilitation in Australia

Nexstim
Regulatory press release25.05.2026 klo 09.00

Nexstim Plc’s New Shares Have Been Registered with the Finnish Trade Register

Nexstim
Regulatory press release18.05.2026 klo 17.00

Nexstim Plc: Disclosure of major holdings under Chapter 9, Section 10 of the Finnish Securities Markets Act

Nexstim
Regulatory press release15.05.2026 klo 14.40

Nexstim Plc: Managers’ Transactions, Järnefelt

Nexstim
Regulatory press release15.05.2026 klo 14.40

Nexstim Plc: Managers’ Transactions, Hannula

Nexstim
Regulatory press release15.05.2026 klo 14.40

Nexstim Plc: Managers’ Transactions, Niemistö

Nexstim